[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

HUT64235A - Process for the production of medical prepartives containing by means of peroral introduction of insuline - Google Patents

Process for the production of medical prepartives containing by means of peroral introduction of insuline

Info

Publication number
HUT64235A
HUT64235A HU9301050A HU105093A HUT64235A HU T64235 A HUT64235 A HU T64235A HU 9301050 A HU9301050 A HU 9301050A HU 105093 A HU105093 A HU 105093A HU T64235 A HUT64235 A HU T64235A
Authority
HU
Hungary
Prior art keywords
prepartives
insuline
medical
production
peroral
Prior art date
Application number
HU9301050A
Other languages
English (en)
Inventor
Howard L Weiner
George Eisenbarth
David A Hafler
Zhengri Zhang
Original Assignee
Autoimmune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Autoimmune Inc filed Critical Autoimmune Inc
Publication of HUT64235A publication Critical patent/HUT64235A/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/542—Mucosal route oral/gastrointestinal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HU9301050A 1990-10-10 1991-10-10 Process for the production of medical prepartives containing by means of peroral introduction of insuline HUT64235A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US59546890A 1990-10-10 1990-10-10

Publications (1)

Publication Number Publication Date
HUT64235A true HUT64235A (en) 1993-12-28

Family

ID=24383359

Family Applications (2)

Application Number Title Priority Date Filing Date
HU9301050A HU225054B1 (en) 1990-10-10 1991-10-10 Process for producing a pharmaceutical composition to protect working ability of pancreas
HU9301050A HUT64235A (en) 1990-10-10 1991-10-10 Process for the production of medical prepartives containing by means of peroral introduction of insuline

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HU9301050A HU225054B1 (en) 1990-10-10 1991-10-10 Process for producing a pharmaceutical composition to protect working ability of pancreas

Country Status (15)

Country Link
US (5) US5763396A (hu)
EP (1) EP0552256B1 (hu)
JP (1) JP2548056B2 (hu)
KR (1) KR100239743B1 (hu)
AT (1) ATE204178T1 (hu)
AU (1) AU659419B2 (hu)
BR (1) BR9106977A (hu)
CA (1) CA2093806C (hu)
DE (1) DE69132688T2 (hu)
DK (1) DK0552256T3 (hu)
ES (1) ES2162615T3 (hu)
HU (2) HU225054B1 (hu)
IL (1) IL99699A (hu)
NO (1) NO319370B1 (hu)
WO (1) WO1992006704A1 (hu)

Families Citing this family (176)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5641474A (en) * 1987-06-24 1997-06-24 Autoimmune, Inc. Prevention of autoimmune diseases by aerosol administration of autoantigens
US5869054A (en) * 1987-06-24 1999-02-09 Autoimmune Inc. Treatment of multiple sclerosis by oral administration of autoantigens
US5571499A (en) * 1987-06-24 1996-11-05 Autoimmune, Inc. Treatment of autoimmune diseases by aerosol administration of autoantigens
US5645820A (en) * 1987-06-24 1997-07-08 Autoimmune, Inc. Treatment of autoimmune diseases by aerosol administration of autoantigens
US5571500A (en) * 1987-06-24 1996-11-05 Autoimmune, Inc. Treatment of autoimmune diseases through administration by inhalation of autoantigens
US6113903A (en) * 1989-03-21 2000-09-05 The Immune Response Corporation Peptides and methods against diabetes
IL99699A (en) 1990-10-10 2002-04-21 Autoimmune Inc Drug with the option of oral, intra-intestinal, or inhaled dosing for suppression of autoimmune response associated with type I diabetes
US7448375B2 (en) * 1993-01-29 2008-11-11 Aradigm Corporation Method of treating diabetes mellitus in a patient
US6024090A (en) * 1993-01-29 2000-02-15 Aradigm Corporation Method of treating a diabetic patient by aerosolized administration of insulin lispro
US5891435A (en) * 1993-04-16 1999-04-06 Research Corporation Technologies, Inc. Methods and compositions for delaying or preventing the onset of autoimmune disease
US6794357B1 (en) * 1993-06-24 2004-09-21 Astrazeneca Ab Compositions for inhalation
US5830853A (en) 1994-06-23 1998-11-03 Astra Aktiebolag Systemic administration of a therapeutic preparation
IS1796B (is) * 1993-06-24 2001-12-31 Ab Astra Fjölpeptíð lyfjablanda til innöndunar sem einnig inniheldur eykjaefnasamband
US20010003739A1 (en) * 1993-06-24 2001-06-14 Astrazeneca Ab Systemic administration of a therapeutic preparation
US6632456B1 (en) 1993-06-24 2003-10-14 Astrazeneca Ab Compositions for inhalation
TW402506B (en) 1993-06-24 2000-08-21 Astra Ab Therapeutic preparation for inhalation
GB9319429D0 (en) * 1993-09-21 1993-11-03 London Health Ass Methods and products for controlling immune responses in mammals
US6165976A (en) 1994-06-23 2000-12-26 Astra Aktiebolag Therapeutic preparation for inhalation
DE69530325T2 (de) 1994-12-22 2004-02-19 Astrazeneca Ab Aerosol-arzneiformulierungen
US6524557B1 (en) 1994-12-22 2003-02-25 Astrazeneca Ab Aerosol formulations of peptides and proteins
DE69530519T2 (de) * 1994-12-22 2004-03-04 Astrazeneca Ab Parathyroidhormon pth enthaltende therapeutische zubereitung zur inhalation
US6428771B1 (en) * 1995-05-15 2002-08-06 Pharmaceutical Discovery Corporation Method for drug delivery to the pulmonary system
WO1997002043A1 (en) * 1995-06-30 1997-01-23 Novo Nordisk A/S Prevention of a disease having the characteristics of diabetes
US6488933B2 (en) 1995-07-05 2002-12-03 Yeda Research And Development Co. Ltd. Preparations for the treatment of T cell mediated diseases
US5856446A (en) * 1995-07-07 1999-01-05 Autoimmune Inc. Method of treating rheumatoid arthritis with low dose type II collagen
WO1997009061A1 (en) * 1995-09-06 1997-03-13 Alexion Pharmaceuticals, Inc. Treatment of diabetes via administration of hormonally ineffective insulin
SE520392C2 (sv) * 1996-09-27 2003-07-01 Creative Peptides Sweden Ab C Specifika peptider för behandling av diabetes mellitus
US20050025758A1 (en) * 1996-10-01 2005-02-03 Harrison Leonard Charles Method and compositions for treatment of insulin-dependant diabetes mellitus
JP2001511187A (ja) * 1997-02-28 2001-08-07 エンゾー セラピュウティクス， インコーポレイテッド 選択的免疫ダウンレギュレーション（ｓｉｄｒ）を行う新規プロセス
US5948407A (en) * 1997-03-19 1999-09-07 Shire Laboratories Inc. Oral induction of tolerance to parenterally administered non-autologous polypeptides
US20060239930A1 (en) * 1997-08-04 2006-10-26 Herbert Lamche Process for nebulizing aqueous compositions containing highly concentrated insulin
DE19733651A1 (de) * 1997-08-04 1999-02-18 Boehringer Ingelheim Pharma Wässrige Aerosolzubereitungen enthaltend biologisch aktive Markomoleküle und Verfahren zur Erzeugung entsprechender Aerosole
US6068844A (en) * 1997-12-19 2000-05-30 The United States Of America As Represented By The Department Of Health And Human Services Increased resistance to stroke by developing immunologic tolerance to myelin or components thereof
US5945123A (en) * 1998-04-02 1999-08-31 K-V Pharmaceutical Company Maximizing effectiveness of substances used to improve health and well being
US20040062802A1 (en) * 1998-04-02 2004-04-01 Hermelin Victor M. Maximizing effectiveness of substances used to improve health and well being
IL126447A (en) * 1998-10-04 2004-09-27 Vascular Biogenics Ltd An immune preparation that confers tolerance in oral administration and its use in the prevention and / or treatment of atherosclerosis
US20050197283A1 (en) * 1998-10-04 2005-09-08 Vascular Biogenics Ltd. Compositions containing beta 2-glycoprotein I for the prevention and/or treatment of vascular disease
US20060171899A1 (en) * 1998-12-10 2006-08-03 Akwete Adjei Water-stabilized aerosol formulation system and method of making
US6417208B1 (en) * 1999-02-05 2002-07-09 Albert Einstein College Of Medicine Of Yeshiva University Method of identification of inhibitors of PDE1C
US7534605B2 (en) * 1999-06-08 2009-05-19 Yissum Research Development Company Of The Hebrew University Of Jerusalem CD44 polypeptides, polynucleotides encoding same, antibodies directed thereagainst and method of using same for diagnosing and treating inflammatory diseases
CA2274414A1 (en) * 1999-06-11 2000-12-11 Universite Laval Dietary fish protein for use in restoring normal insulin function insulin-resistant individuals
WO2001000654A2 (en) * 1999-06-29 2001-01-04 Pharmaceutical Discovery Corporation Purification and stabilization of peptide and proteins in pharmaceutical agents
US9006175B2 (en) 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
US6540982B1 (en) * 2000-01-25 2003-04-01 Aeropharm Technology Incorporated Medical aerosol formulation
US7166280B2 (en) * 2000-04-06 2007-01-23 Franco Wayne P Combination growth factor therapy and cell therapy for treatment of acute and chronic heart disease
US20100303769A1 (en) * 2000-04-06 2010-12-02 Franco Wayne P Combination growth factor therapy and cell therapy for treatment of acute and chronic heart disease
US6543682B1 (en) 2000-05-03 2003-04-08 Nichole Glaser Insulin-dose calculator disk
US7462486B2 (en) * 2000-05-12 2008-12-09 Oregon Health & Science University Methods of selecting T cell receptor V peptides for therapeutic use
CA2408935A1 (en) * 2000-05-12 2001-11-15 Halina Offner Method of treating immune pathologies with low dose estrogen
ES2292594T3 (es) 2000-05-24 2008-03-16 The Government Of The Usa As Represented By The Secretary Of Department Of Health And Human Services E-selectina para tratar o prevenir accidentes cerebrovasculares.
US6867183B2 (en) * 2001-02-15 2005-03-15 Nobex Corporation Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
US7060675B2 (en) * 2001-02-15 2006-06-13 Nobex Corporation Methods of treating diabetes mellitus
CN1507362A (zh) * 2001-05-04 2004-06-23 �Ʒ� 利用雾化的胰岛素预防ⅱ型糖尿病的方法
US7713932B2 (en) * 2001-06-04 2010-05-11 Biocon Limited Calcitonin drug-oligomer conjugates, and uses thereof
US6835802B2 (en) * 2001-06-04 2004-12-28 Nobex Corporation Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties
US6828297B2 (en) * 2001-06-04 2004-12-07 Nobex Corporation Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6828305B2 (en) * 2001-06-04 2004-12-07 Nobex Corporation Mixtures of growth hormone drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6858580B2 (en) * 2001-06-04 2005-02-22 Nobex Corporation Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US6713452B2 (en) * 2001-06-04 2004-03-30 Nobex Corporation Mixtures of calcitonin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US7196059B2 (en) * 2001-09-07 2007-03-27 Biocon Limited Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
US20030198666A1 (en) * 2002-01-07 2003-10-23 Richat Abbas Oral insulin therapy
CA2479751C (en) 2002-03-20 2008-06-03 Trent Poole Inhalation apparatus
EP1621210B1 (en) * 2003-04-28 2013-06-19 Daiichi Sankyo Company, Limited Adiponectin production enhancer
WO2004096276A1 (ja) * 2003-04-28 2004-11-11 Sankyo Company, Limited 糖取り込み能増強剤
US7338171B2 (en) * 2003-10-27 2008-03-04 Jen-Chuen Hsieh Method and apparatus for visual drive control
CN101027082A (zh) * 2004-01-12 2007-08-29 曼恩坎德公司 降低2型糖尿病患者血清胰岛素原水平的方法
US20080090753A1 (en) 2004-03-12 2008-04-17 Biodel, Inc. Rapid Acting Injectable Insulin Compositions
US20080096800A1 (en) * 2004-03-12 2008-04-24 Biodel, Inc. Rapid mucosal gel or film insulin compositions
EP2106790B1 (en) * 2004-03-12 2012-10-24 Biodel, Inc. Rapid acting drug delivery compositions
US20080085298A1 (en) * 2004-03-12 2008-04-10 Biodel, Inc. Rapid Mucosal Gel or Film Insulin Compositions
CA2570916C (en) 2004-06-16 2013-06-11 Tap Pharmaceutical Products, Inc. Pulsed release dosage form of a ppi
PT1773878E (pt) 2004-07-19 2015-06-05 Biocon Ltd Conjugados de insulina-oligómero, formulaçôes e usos dos mesmos
WO2006012641A2 (en) * 2004-07-30 2006-02-02 Oregon Health And Science University Methods for detecting and treating autoimmune disorders
DE602005024413D1 (de) 2004-08-20 2010-12-09 Mannkind Corp Katalyse der diketopiperazinsynthese
EP2314298B1 (en) 2004-08-23 2015-05-27 MannKind Corporation Microparticles comprising diketopiperazine salts for drug delivery
EP1874334A4 (en) * 2005-04-15 2011-03-30 Vascular Biogenics Ltd COMPOSITIONS WITH BETA 2-GLYCOPROTEIN I-PEPTIDES FOR THE PREVENTION AND / OR TREATMENT OF VASCULAR DISEASES
RU2390325C2 (ru) 2005-09-14 2010-05-27 Маннкайнд Корпорейшн Способ приготовления лекарственного препарата, основанный на увеличении сродства активных агентов к поверхностям кристаллических микрочастиц
EP1931665A1 (en) 2005-09-20 2008-06-18 Schering Corporation 1-[[1-[(2-amin0-6-methyl-4-pyridinyl)methyl]-4-flu0r0-4-piperidinyl,]carbonyl]-4-[2-(2-pyridinyl)-3h-imidaz0[4, 5-b]pyridin-3-yl]piperidine useful as histamine h3 antagonist
US7713929B2 (en) 2006-04-12 2010-05-11 Biodel Inc. Rapid acting and long acting insulin combination formulations
US8084420B2 (en) * 2005-09-29 2011-12-27 Biodel Inc. Rapid acting and long acting insulin combination formulations
US20070086952A1 (en) * 2005-09-29 2007-04-19 Biodel, Inc. Rapid Acting and Prolonged Acting Inhalable Insulin Preparations
WO2007098500A2 (en) 2006-02-22 2007-08-30 Mannkind Corporation A method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent
MX2008013165A (es) * 2006-04-12 2009-01-29 Biodel Inc Formulaciones de combinacion de insulina de accion rapida y accion larga.
US8217025B2 (en) * 2006-11-17 2012-07-10 Harbor Therapeutics, Inc. Drug screening and treatment methods
ES2579229T3 (es) 2007-03-13 2016-08-08 Jds Therapeutics, Llc Procedimientos y composiciones para la liberación sostenida de cromo
WO2008124522A2 (en) * 2007-04-04 2008-10-16 Biodel, Inc. Amylin formulations
EA020466B1 (ru) 2007-06-04 2014-11-28 Синерджи Фармасьютикалз Инк. Агонисты гуанилатциклазы, пригодные для лечения желудочно-кишечных нарушений, воспаления, рака и других заболеваний
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
WO2009002867A2 (en) 2007-06-26 2008-12-31 Nutrition 21, Inc. Multiple unit dosage form having a therapeutic agents in combination with a nutritional supplement
RU2013106514A (ru) 2007-10-12 2015-03-10 Такеда Фармасьютикалз Норт Америка, Инк. Способы лечения нарушений желудочно-кишечного тракта независимо от потребления пищи
ES2664822T3 (es) 2007-10-16 2018-04-23 Biocon Limited Una composición farmacéutica sólida administrable por vía oral y un proceso de la misma
US8907095B2 (en) 2007-10-22 2014-12-09 Merck Sharp & Dohme Corp. Bicyclic heterocycle derivatives and their use as modulators of the activity of GPR119
EP2077132A1 (en) 2008-01-02 2009-07-08 Boehringer Ingelheim Pharma GmbH & Co. KG Dispensing device, storage device and method for dispensing a formulation
WO2009089181A1 (en) * 2008-01-04 2009-07-16 Blodel, Inc. Insulin formulations for insulin release as a function of tissue glucose levels
US20110065671A1 (en) 2008-05-19 2011-03-17 Harris Joel M Bicyclic heterocycle derivatives and use thereof as gpr119 modulators
CA2930674A1 (en) 2008-06-04 2009-12-10 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
CN101827626B (zh) 2008-06-13 2015-03-18 曼金德公司 干粉吸入器和用于药物输送的系统
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
JP5479465B2 (ja) 2008-06-20 2014-04-23 マンカインド コーポレイション 吸入努力をリアルタイムにプロファイルする対話式機器および方法
JP2011528375A (ja) 2008-07-16 2011-11-17 シナジー ファーマシューティカルズ インコーポレイテッド 胃腸障害、炎症、癌、およびその他の障害の治療のために有用なグアニル酸シクラーゼのアゴニスト
CN102159572A (zh) 2008-07-16 2011-08-17 先灵公司 双环杂环衍生物及其作为gpr 119调节剂的用途
US20110166124A1 (en) 2008-07-23 2011-07-07 Mccormick Kevin D Tricyclic spirocycle derivatives and methods of use
TWI494123B (zh) 2008-08-11 2015-08-01 Mannkind Corp 超快起作用胰島素之用途
EP2350020B1 (en) 2008-10-03 2014-08-13 Merck Sharp & Dohme Corp. Spiro-imidazolone derivatives as glucagon receptor antagonists
AU2009303444A1 (en) 2008-10-16 2010-04-22 Schering Corporation Azine derivatives and methods of use thereof
WO2010075068A1 (en) 2008-12-16 2010-07-01 Schering Corporation Pyridopyrimidine derivatives and methods of use thereof
EP2379562A1 (en) 2008-12-16 2011-10-26 Schering Corporation Bicyclic pyranone derivatives as nicotinic acid receptor agonists
EP2379565A1 (en) 2008-12-19 2011-10-26 Schering Corporation Piperidine and piperazine derivatives and methods of use thereof
WO2010071819A1 (en) 2008-12-19 2010-06-24 Schering Corporation Bicyclic heterocyclic derivatives and methods of use thereof
WO2010075273A1 (en) 2008-12-23 2010-07-01 Schering Corporation Bicyclic heterocycle derivatives and methods of use thereof
CA2747807A1 (en) 2008-12-23 2010-07-01 Bernard R. Neustadt Pyrimidine derivatives and methods of use thereof
EP2382203B1 (en) 2008-12-23 2015-01-14 Merck Sharp & Dohme Corp. Bicyclic heterocycle derivatives and methods of use thereof
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
KR20110104081A (ko) 2009-01-28 2011-09-21 스마트쎌스, 인크. 제어 약물 전달을 위한 접합체 기재 시스템
WO2010092218A2 (es) 2009-02-12 2010-08-19 Proyecto De Biomedicina Cima, S.L. Uso de la cardiotrofina-1 para el tratamiento de enfermedades metabólicas
US9060927B2 (en) * 2009-03-03 2015-06-23 Biodel Inc. Insulin formulations for rapid uptake
EP2676695A3 (en) 2009-03-11 2017-03-01 MannKind Corporation Apparatus, system and method for measuring resistance of an inhaler
AU2010226826A1 (en) 2009-03-18 2011-10-13 Merck Sharp & Dohme Corp. Bicyclic compounds as inhibitors of diacylglycerol acyltransferase
JP5670421B2 (ja) 2009-03-31 2015-02-18 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング コンポーネント表面のコーティング方法
US8580807B2 (en) 2009-04-03 2013-11-12 Merck Sharp & Dohme Corp. Bicyclic piperidine and piperazine derivatives as GPCR modulators for the treatment of obesity, diabetes and other metabolic disorders
AR076024A1 (es) 2009-04-03 2011-05-11 Schering Corp Derivados de heterociclos biciclicos puenteados y metodos de uso de los mismos
EP3508239B1 (de) 2009-05-18 2020-12-23 Boehringer Ingelheim International GmbH Adapter, inhalationseinrichtung und zerstäuber
US8734845B2 (en) 2009-06-12 2014-05-27 Mannkind Corporation Diketopiperazine microparticles with defined specific surface areas
EP2440553B1 (en) 2009-06-12 2017-08-23 Merck Sharp & Dohme Corp. Thiophenes as glucagon receptor antagonists, compositions, and methods for their use
WO2011031628A1 (en) 2009-09-14 2011-03-17 Schering Corporation Inhibitors of diacylglycerol acyltransferase
EP2485735B1 (en) 2009-10-08 2015-07-29 Merck Sharp & Dohme Corp. Inhibitors of fatty acid binding protein (fabp)
CA2778684A1 (en) 2009-10-29 2011-05-05 Schering Corporation Bridged bicyclic piperidine derivatives and methods of use thereof
JP5784622B2 (ja) 2009-11-03 2015-09-24 マンカインド コーポレ−ション 吸入活動をシミュレートするための装置及び方法
US20120232073A1 (en) 2009-11-23 2012-09-13 Santhosh Francis Neelamkavil Fused bicyclic pyrimidine derivatives and methods of use thereof
WO2011062889A1 (en) 2009-11-23 2011-05-26 Schering Corporation Pyrimidine ether derivatives and methods of use thereof
EP2503887B1 (en) 2009-11-24 2016-01-06 Merck Sharp & Dohme Corp. Substituted biaryl derivatives and methods of use thereof
JP5658268B2 (ja) 2009-11-25 2015-01-21 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ネブライザ
EA026241B1 (ru) 2009-11-25 2017-03-31 Бёрингер Ингельхайм Интернациональ Гмбх Распылитель
US10016568B2 (en) 2009-11-25 2018-07-10 Boehringer Ingelheim International Gmbh Nebulizer
BR112012033060A2 (pt) 2010-06-21 2018-02-27 Mannkind Corp métodos de sistema de liberação de fármaco em pó seco
WO2011160932A1 (en) 2010-06-24 2011-12-29 Boehringer Ingelheim International Gmbh Nebulizer
US9074015B2 (en) 2010-07-28 2015-07-07 Smartcells, Inc. Recombinantly expressed insulin polypeptides and uses thereof
WO2012027331A1 (en) 2010-08-27 2012-03-01 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
US8603527B2 (en) * 2010-10-25 2013-12-10 Signal Pharmaceuticals, Llc Pharmaceutical formulations of a substituted diaminopurine
EP2680861B1 (en) 2011-03-01 2022-05-04 Nutrition 21, LLC Compositions of insulin and chromium for the treatment and prevention of diabetes, hypoglycemia and related disorders
WO2012130757A1 (de) 2011-04-01 2012-10-04 Boehringer Ingelheim International Gmbh Medizinisches gerät mit behälter
SG194034A1 (en) 2011-04-01 2013-11-29 Mannkind Corp Blister package for pharmaceutical cartridges
US9827384B2 (en) 2011-05-23 2017-11-28 Boehringer Ingelheim International Gmbh Nebulizer
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
AU2012328885B2 (en) 2011-10-24 2017-08-31 Mannkind Corporation Methods and compositions for treating pain
WO2013152894A1 (de) 2012-04-13 2013-10-17 Boehringer Ingelheim International Gmbh Zerstäuber mit kodiermitteln
BR112015000529B1 (pt) 2012-07-12 2022-01-11 Mannkind Corporation Inalador de pó seco
US9486433B2 (en) 2012-10-12 2016-11-08 Mochida Pharmaceuticals Co. Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
WO2014066856A1 (en) 2012-10-26 2014-05-01 Mannkind Corporation Inhalable influenza vaccine compositions and methods
AU2014235215A1 (en) 2013-03-15 2015-10-01 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
JP2016514670A (ja) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド 他の薬物と組み合わせたグアニル酸シクラーゼ受容体アゴニスト
US10441560B2 (en) 2013-03-15 2019-10-15 Mochida Pharmaceutical Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
KR102499439B1 (ko) 2013-03-15 2023-02-13 맨카인드 코포레이션 미세결정성 디케토피페라진 조성물 및 방법
SG11201507288UA (en) 2013-03-15 2015-10-29 Mochida Pharm Co Ltd Compositions and methods for treating non-alcoholic steatohepatitis
US10011637B2 (en) 2013-06-05 2018-07-03 Synergy Pharmaceuticals, Inc. Ultra-pure agonists of guanylate cyclase C, method of making and using same
MX2020009878A (es) 2013-07-18 2022-07-27 Mannkind Corp Composiciones farmaceuticas en polvo seco estables al calor y metodos.
JP2016530930A (ja) 2013-08-05 2016-10-06 マンカインド コーポレイション 通気装置及び方法
ES2836977T3 (es) 2013-08-09 2021-06-28 Boehringer Ingelheim Int Nebulizador
US9744313B2 (en) 2013-08-09 2017-08-29 Boehringer Ingelheim International Gmbh Nebulizer
MX366852B (es) 2013-10-04 2019-07-25 Merck Sharp & Dohme Conjugados de insulina sensibles a glucosa.
US10307464B2 (en) 2014-03-28 2019-06-04 Mannkind Corporation Use of ultrarapid acting insulin
US10716907B2 (en) 2014-05-07 2020-07-21 Boehringer Ingelheim International Gmbh Nebulizer
BR112016023983B1 (pt) 2014-05-07 2022-10-18 Boehringer Ingelheim International Gmbh Contentor para um nebulizador, nebulizador para um fluido e método para conectar um contentor a um dispositivo indicador
PL3139984T3 (pl) 2014-05-07 2021-11-08 Boehringer Ingelheim International Gmbh Nebulizator
CN107001442B (zh) 2014-07-15 2021-04-27 耶路撒冷希伯来大学伊森姆研究发展公司 Cd44的分离的多肽及其应用
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler
PL3204386T3 (pl) 2014-10-06 2021-09-20 Signal Pharmaceuticals, Llc Podstawione związki aminopurynowe, ich kompozycje i sposoby leczenia nimi
CA2936740C (en) 2014-10-31 2017-10-10 Purdue Pharma Methods and compositions particularly for treatment of attention deficit disorder
WO2017139337A1 (en) 2016-02-11 2017-08-17 Nutrition 21, Llc Chromium containing compositions for improving health and fitness
MX2018011970A (es) 2016-04-01 2019-05-20 Signal Pharm Llc Formas sólidas de (1s,4s)-4-(2-(((3s,4r)-3-fluorotetrahidro-2h-pir an-4-il)amino)-8-((2,4,6-triclorofenilo)amino)-9h-purin-9-il)-1-m etilciclohexano-1-carboxamida y métodos para utilizarlas.
NZ746554A (en) 2016-04-01 2023-03-31 Signal Pharm Llc Substituted aminopurine compounds, compositions thereof, and methods of treatment therewith
JP2020536100A (ja) 2017-10-04 2020-12-10 セルジーン コーポレイション シス−４−［２−｛［（３ｓ，４ｒ）−３−フルオロキサン−４−イル］アミノ｝−８−（２，４，６−トリクロロアニリノ）−９ｈ−プリン−９−イル］−１−メチルシクロヘキサン−１−カルボキサミドの製造プロセス
BR122022005778B1 (pt) 2017-10-04 2024-01-09 Celgene Corporation Cápsula compreendendo cis-4-[2-{[(3s,4r)-3-fluoro-oxan-4-il]amino}-8-(2,4,6-tricloroanilino)-9h-purin-9-il]-1-metilciclohexano-1-carboxamida
US10722473B2 (en) 2018-11-19 2020-07-28 Purdue Pharma L.P. Methods and compositions particularly for treatment of attention deficit disorder
WO2023200363A1 (ru) * 2022-04-13 2023-10-19 Фания Иршатовна МАГАНОВА Способ получения пероральной формы субстанции, содержащей инсулин

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3561444A (en) * 1968-05-22 1971-02-09 Bio Logics Inc Ultrasonic drug nebulizer
US3594476A (en) * 1969-05-12 1971-07-20 Massachusetts Inst Technology Submicron aqueous aerosols containing lecithin
US3703173A (en) * 1970-12-31 1972-11-21 Ted A Dixon Nebulizer and tent assembly
US4153689A (en) * 1975-06-13 1979-05-08 Takeda Chemical Industries, Ltd. Stable insulin preparation for nasal administration
GB1527605A (en) * 1975-08-20 1978-10-04 Takeda Chemical Industries Ltd Insulin preparation for intranasal administration
US4309406A (en) * 1979-07-10 1982-01-05 American Home Products Corporation Sustained release pharmaceutical compositions
US4309404A (en) * 1979-08-09 1982-01-05 American Home Products Corporation Sustained release pharmaceutical compositions
IT1133010B (it) * 1980-05-15 1986-07-09 Sigma Tau Ind Farmaceuti Metodo terapuetico per il trattamento del diabete mellito a insorgenza giovanile e composizione farmaceutica per tale metodo
DK283180A (da) * 1980-07-01 1982-01-02 Novo Industri As Polypeptider og derivater deraf
SU1011126A1 (ru) * 1981-07-14 1983-04-15 Всесоюзный научно-исследовательский и испытательный институт медицинской техники Средство дл лечени сахарного диабета
US4659696A (en) * 1982-04-30 1987-04-21 Takeda Chemical Industries, Ltd. Pharmaceutical composition and its nasal or vaginal use
JPS59163313A (ja) * 1983-03-09 1984-09-14 Teijin Ltd 経鼻投与用ペプチドホルモン類組成物
IL68769A (en) * 1983-05-23 1986-02-28 Hadassah Med Org Pharmaceutical compositions containing insulin for oral administration
DE3326473A1 (de) * 1983-07-22 1985-01-31 Hoechst Ag, 6230 Frankfurt Pharmazeutisches mittel zur behandlung des diabetes mellitus
US4556552A (en) * 1983-09-19 1985-12-03 Colorcon, Inc. Enteric film-coating compositions
US4704295A (en) * 1983-09-19 1987-11-03 Colorcon, Inc. Enteric film-coating compositions
US4963367A (en) * 1984-04-27 1990-10-16 Medaphore, Inc. Drug delivery compositions and methods
WO1985005029A1 (en) * 1984-05-09 1985-11-21 Medaphore Inc. Oral insulin and a method of making the same
US4963526A (en) * 1984-05-09 1990-10-16 Synthetic Blood Corporation Oral insulin and a method of making the same
US4635627A (en) * 1984-09-13 1987-01-13 Riker Laboratories, Inc. Apparatus and method
US4624251A (en) * 1984-09-13 1986-11-25 Riker Laboratories, Inc. Apparatus for administering a nebulized substance
JPS61194034A (ja) * 1985-02-25 1986-08-28 Teijin Ltd 経鼻投与用粉末状組成物
EP0200383A3 (en) * 1985-04-15 1987-09-02 Eli Lilly And Company An improved method for administering insulin
IL77186A0 (en) * 1985-11-29 1986-04-29 Touitou Elka Pharmaceutical insulin composition
DK179286D0 (da) * 1986-04-18 1986-04-18 Nordisk Gentofte Insulinpraeparat
JPS62267238A (ja) * 1986-05-15 1987-11-19 R P Shiila- Kk インシユリン坐剤の製法
CH671155A5 (hu) * 1986-08-18 1989-08-15 Clinical Technologies Ass
GB8622218D0 (en) * 1986-09-16 1986-10-22 Renishaw Plc Calibration for automatic machine tool
NZ222907A (en) * 1986-12-16 1990-08-28 Novo Industri As Preparation for intranasal administration containing a phospholipid absorption enhancing system
US5112804A (en) * 1987-04-01 1992-05-12 Temple University Of The Commonwealth System Of Higher Education Pharmaceutical composition and method of intranasal administration
US5571500A (en) 1987-06-24 1996-11-05 Autoimmune, Inc. Treatment of autoimmune diseases through administration by inhalation of autoantigens
US5399347A (en) 1987-06-24 1995-03-21 Autoimmune, Inc. Method of treating rheumatoid arthritis with type II collagen
US5843445A (en) 1987-06-24 1998-12-01 Autoimmune, Inc. Method of treating rheumatoid arthritis with type II collagen
US5645820A (en) 1987-06-24 1997-07-08 Autoimmune, Inc. Treatment of autoimmune diseases by aerosol administration of autoantigens
US5571499A (en) 1987-06-24 1996-11-05 Autoimmune, Inc. Treatment of autoimmune diseases by aerosol administration of autoantigens
US5849298A (en) 1987-06-24 1998-12-15 Autoimmune Inc. Treatment of multiple sclerosis by oral administration of bovine myelin
US5641474A (en) 1987-06-24 1997-06-24 Autoimmune, Inc. Prevention of autoimmune diseases by aerosol administration of autoantigens
ATE130762T1 (de) * 1987-06-24 1995-12-15 Autoimmune Inc Behandlung von autoimmun-erkrankungen durch orale verabreichung von autoantigenen.
US4992417A (en) * 1987-07-17 1991-02-12 Mount Sinai School Of Medicine Superactive human insulin analogues
US4789660A (en) * 1987-09-10 1988-12-06 American Home Products Corporation Insulin administration using methyl and propyl paraben
PT88490B (pt) * 1987-09-14 1992-11-30 Novo Nordisk As Processo para a preparacao de composicoes farmaceuticas para libertacao nao-enterica trans-mucosa contendo monossacaridos ou oligossacaridos
DE68909135T2 (de) * 1988-07-21 1994-04-07 Hoffmann La Roche Insulinzubereitung.
US5011678A (en) * 1989-02-01 1991-04-30 California Biotechnology Inc. Composition and method for administration of pharmaceutically active substances
US5171737A (en) * 1989-03-03 1992-12-15 The Liposome Company, Inc. Emulsions
KR0159046B1 (ko) 1989-07-14 1998-11-16 배리 와인버그 포유류의 자기면역 포도막망막염의 치료 또는 예방방법
ES2144398T3 (es) * 1989-12-20 2000-06-16 Autoimmune Inc Tratamiento mejorado de enfermedades autoinmunes mediante la administracion en aerosol de autoantigenos.
DK0594607T3 (da) 1990-03-02 1998-04-14 Autoimmune Inc Forøgelse af nedreguleringen af autoimmune sygdomme ved oral eller enteral indgivelse af autoantigener
IL97709A (en) 1990-03-30 2005-05-17 Brigham & Womens Hospital Use of an mbp peptide for the preparation of a medicament for the treatment of multiple sclerosis
IL99699A (en) * 1990-10-10 2002-04-21 Autoimmune Inc Drug with the option of oral, intra-intestinal, or inhaled dosing for suppression of autoimmune response associated with type I diabetes
US5593698A (en) 1990-10-31 1997-01-14 Autoimmune, Inc. Suppression of proliferative response and induction of tolerance with polymorphic class II MHC allopeptides
IL99864A (en) 1990-10-31 2000-11-21 Autoimmune Inc Compositions for suppressing transplant rejection in mammals which contain tissue donor derived MHC antigens
US5321009A (en) * 1991-04-03 1994-06-14 American Home Products Corporation Method of treating diabetes
US5672581A (en) * 1993-01-29 1997-09-30 Aradigm Corporation Method of administration of insulin
TW402506B (en) * 1993-06-24 2000-08-21 Astra Ab Therapeutic preparation for inhalation

Also Published As

Publication number Publication date
KR100239743B1 (ko) 2000-02-01
IL99699A0 (en) 1992-08-18
JP2548056B2 (ja) 1996-10-30
ES2162615T3 (es) 2002-01-01
US5643868A (en) 1997-07-01
DE69132688T2 (de) 2001-11-29
BR9106977A (pt) 1993-08-31
JPH06504986A (ja) 1994-06-09
NO319370B1 (no) 2005-07-25
KR930702022A (ko) 1993-09-08
EP0552256B1 (en) 2001-08-16
US5858968A (en) 1999-01-12
CA2093806C (en) 2003-12-30
ATE204178T1 (de) 2001-09-15
AU8767991A (en) 1992-05-20
DE69132688D1 (de) 2001-09-20
AU659419B2 (en) 1995-05-18
NO931267L (no) 1993-05-05
CA2093806A1 (en) 1992-04-11
EP0552256A1 (en) 1993-07-28
EP0552256A4 (hu) 1994-04-27
DK0552256T3 (da) 2001-12-10
US5843886A (en) 1998-12-01
WO1992006704A1 (en) 1992-04-30
IL99699A (en) 2002-04-21
US5763396A (en) 1998-06-09
US20010056063A1 (en) 2001-12-27
US6703361B2 (en) 2004-03-09
NO931267D0 (no) 1993-04-01
HU225054B1 (en) 2006-05-29

Similar Documents

Publication Publication Date Title
HUT64235A (en) Process for the production of medical prepartives containing by means of peroral introduction of insuline
NL990012I1 (nl) Geneesmiddelen die salmeterol en fluticason bevatten.
ATE94393T1 (de) Dosisform zur oralen verabreichung des hypoglykaemischen glipizids.
GR3031448T3 (en) Advanced drug delivery system and method of treating psychiatric, neurological and other disorders with carbamazepine.
ATE233262T1 (de) Pcp-rezeptor-liganden und deren verwendung
ATE178793T1 (de) L-dopa ester-enthaltende zusammensetzung
ZA884670B (en) Process for producing an administration and/or dosage form for medicinal active substances by means of a printing process
SE9702401D0 (sv) Pharmaceutical use
GR3018365T3 (en) Use of 15-deoxyspergualine as a medicament.
HUT59827A (en) Process for producing pharmaceutical compositions containing pafantagonistic thieno-triazolo-diazepines for treating heart diseases produced by diminished beta-receptor-stimulant
DE3480325D1 (en) Pharmaceutical dosage unit
UA10248A (uk) Спосіб лікування ішемічної хвороби серця на фоні цукрового діабету
IT1259140B (it) Formulazioni farmaceutiche per la somministraziane orale di calcitonina
MY111155A (en) Medicaments